TEVJF - Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update
2025-09-02 21:37:27 ET
This article is part of a series that provides an ongoing analysis of the changes made to Duquesne Family Office's 13F stock portfolio on a quarterly basis. It is based on Stanley Druckenmiller's regulatory 13F Form filed on 08/15/2025. The 13F portfolio value increased from $3.06B to $4.07B this quarter. The holdings are concentrated with recent 13F reports showing around 70 positions, many of which are very small. There are 38 securities that are significantly large (more than ~0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are Natera, Teva Pharma, Insmed, Woodward, and Taiwan Semi. They add up to ~35% of the portfolio. Please visit our Tracking Stanley Druckenmiller's Duquesne Portfolio series to get an idea of their investment philosophy and our previous update for the fund's moves during Q1 2025....
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update